ArticlePloS one2012

Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer.

Ibrahim Tekedereli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.